These groups reported sensitivities from 78% to 88%. Another study using radionuclide ventriculographic indexes of diastolic function reported similar results.12 Unfortunately, other studies13"4 have reported that diastolic dysfunction is common early after cardiac transplantation (probably related to ischemic injury) and may take as much as 3 months to completely resolve. In addition, Valantine et al15 and others16 report late "restrictive" physiology after cardiac transplantation. Additional factors such as donor-recipient size matching may play an important role in the diastolic properties of the allograft.1417 Based on the available data, one must therefore conclude that functional indexes by themselves are unlikely to provide the sensitivity required for rejection screening of asymptomatic patients.
The second major area of investigation has attempted to directly assay for increases in alloimmunologic activity. The earliest studies reported by Copeland and colleagues18,19 involved the measurement of urinary polyamines that reflected increased cellular proliferation or degeneration. This same group20 also evaluated changes in prolactin levels, a potential indication of immune modulation, as a noninvasive screen for rejection. Again, the sensitivity of these studies was approximately 80%. With the further understanding of immunologic activation, lymphocyte subsets, and activation markers, along with the development of flow cytometry techniques, several groups21-23 have investigated the possibility that the expression of activation antigens on circulating lymphocytes might predict rejection. Although one group23 reported a sensitivity of 94% for the detection of rejection using cytoimmunologic monitoring, these striking results have not been confirmed by others. 21 11In has been demonstrated to be useful in the diagnosis of myocardial infarction30 and myocarditis.31 In this issue of Circulation, Ballester and colleagues32 have extended their experience using indium-labeled antimyosin antibodies in the diagnosis of acute cellular cardiac allograft rejection. In their initial experience of 53 studies in 21 patients,33 an abnormal antimyosin uptake ratio (greater than 1.55) yielded a sensitivity of 95% for the diagnosis of rejection requiring treatment (moderate or severe rejection). As might be anticipated, specificity was quite low (29%), with a majority of patients with no rejection also exhibiting antimyosin uptake ratios out of the normal range. In a follow-up study of patients at least 1 year after cardiac transplantation,34 a negative antimyosin antibody scan assured the absence of rejection requiring treatment (sensitivity, 100%), with four of the 11 patients with positive scans demonstrating clinically significant rejection (specificity, 33%). Specificity, as anticipated, increased with an increasingly abnormal scan. Thus, both early and late after cardiac transplantation, scanning with indium-labeled antimyosin appears to be nearly 100% sensitive but not specific. Based on these data, approximately one third of all biopsies on stable patients could therefore be avoided.
The current study incorporates patients from the previous two investigations but most importantly provides an additional 22 patients who are prospectively and serially studied at multiple time points in the first year after cardiac transplantation. The normal pattern of myocardial injury as assessed by allograft antimyosin antibody uptake over time can therefore be described. As reported, it appears that initially antimyosin uptake can be abnormal but should decrease steadily toward normal by approximately 3 months. By inference, myocardial injury sufficient to cause sarcolemmal disruption from initial ischemic injury, immunologic mechanisms, or other factors may persist for up to 3 months, with gradual resolution. These data would also suggest that if alloimmunologic injury is the mechanism, traditional cell-mediated rejection is an incomplete explanation, given the multiple negative biopsies during this period. In those patients who followed this normal pattern (15 of 33), their long-term follow-up was uneventful. In those 10 patients who exhibited persistent elevations in antimyosin antibody uptake, their course was less well defined, with three patients succumbing to acute cellular rejection.
The strength of this study is the definition of the normal pattern of diminishing antimyosin antibody uptake and by inference, myocardial injury over time after cardiac transplantation in a prospective, serially studied cohort. Any interpretation or therapeutic intervention based on an abnormal antimyosin antibody uptake pattern should at this time be at best cautious. Although the authors suggest that this abnormal pattern of antimyosin antibody uptake bodes poorly for the patient, the evidence for this is not strong. Of the 10 patients studied, three patients did well. Only three had clearly established immunologic consequences (cellular rejection). One additional patient had an abnormal ejection fraction potentially caused by any number of factors (donor factors, ischemic preservation injury, or rejection), and two patients had "vascular rejection," a frequently used diagnosis but poorly defined entity (or nonentity). Finally, given the extremely low 1-month survival rate of their transplant experience during this prospective study, selection bias may play a role in overall outcome.
The confusion over both the mechanisms and the diagnosis of immune-mediated myocardial injury is not new. Most transplant physicians have experienced patients with multiple episodes of severe histological rejection who despite this maintain normal allograft function and conversely, patients presenting with cardiogenic shock who on biopsy or even autopsy have trivial interstitial infiltrates, minimal necrosis, and possibly some myocardial edema. Our current understanding of the rejection process is still quite primitive. Ongoing research such as the characterization of specific cell types invading the allograft, the role of cytokines in myocardial injury, and the probability of humoral injury to both the myocardium and the allograft vasculature will hopefully reduce this confusion.
The authors should be commended for this study. First, they have provided data, which to date best define the expected and presumably normal pattern of antimyosin antibody uptake in the human cardiac allograft. Second, they have by inference identified this methodology as a tool of exquisite sensitivity for the detection of allograft myocardial injury (at a time when histology is normal). This may be extremely important in attempting to better delineate immune mechanisms of myocardial injury. Finally, assuming confirmation by other investigators, they have demonstrated that this methodology could result in a reduction in the number of surveillance endomyocardial biopsies after cardiac transplantation. Certainly this represents a "grail" for both transplant physicians and their patients.
